



February 16, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 30 read with Schedule III of the Listing Regulations and with reference to our earlier intimation dated March 1, 2025, we wish to inform you that the Company has received an Order dated February 16, 2026 issued by the Joint Commissioner of State Tax, State GST (Appeals), Nagpur, Maharashtra, in respect of Company’s appeal filed against the order passed by the Deputy Commissioner of State Tax, Nagpur, Maharashtra under Section 73 of the CGST Act, 2017, dropping the penalty INR 46,32,582/-.

The detailed disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/ PoD2/CIR/P/0155 dated November 11, 2024 for aforesaid is enclosed as Annexure I.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Annexure – I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/ PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Details of event that needs to be provided	Details
1	Name of the authority	Joint Commissioner of State Tax, State GST (Appeals), Nagpur, Maharashtra
2	Nature and details of the action(s) taken, initiated or order(s) passed;	Order-in-Appeal No. 02/286 dated February 16, 2026 against the Order-in-Original dated February 28, 2025 passed u/s 73 of Central Goods and Services Tax Act, 2017 for financial year 2020-21 dropping the demand of penalty of INR 46,32,582/- imposed in O.I.O
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	Order-in-Appeal No. 02/286 dated February 16, 2026 received against the appeal filed by the Company against Order dated February 28, 2025.
4	Details of the violation(s)/contravention(s) committed or alleged to be committed;	N.A
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	N.A

MANKIND PHARMA LIMITED